21 General Introduction 31. Di Minno G, Castaman G, De Cristofaro R, Brunetti-Pierri N, Pastore L, Castaldo G, Trama U, Di Minno M. Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy. Blood Rev. 2022: 101011. 32. De Vries T, Henning R, Hogerzeil H, Fresle D. Guide to good prescribing. World Health Organisation, Geneva. 1994. 33. Tichelaar J, Richir MC, Garner S, Hogerzeil H, de Vries T. WHO guide to good prescribing is 25 years old: quo vadis? Eur J Clin Pharmacol. 2020; 76: 507-513. 34. Geerts AF, De Koning FH, Van Solinge WW, De Smet PA, Egberts TC. Instructions on laboratory monitoring in 200 drug labels. Clin Chem Lab Med. 2012; 50: 1351-1358. 35. Papamichael K, Vogelzang EH, Lambert J, Wolbink G, Cheifetz AS. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases. Expert Rev Clin Immunol. 2019; 15: 837-848. 36. Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost. 2016; 14: 248-261. 37. Muller J, Miesbach W, Pruller F, Siegemund T, Scholz U, Sachs UJ, Standing Commission Labor of the Society of T, Haemostasis R. An Update on Laboratory Diagnostics in Haemophilia A and B. Hamostaseologie. 2022; 42: 248-260. 38. Kitchen S, Jennings I, Makris M, Kitchen DP, Woods TA, Walker ID. Factor VIII assay variability in postinfusion samples containing full length and B-domain deleted FVIII. Haemophilia. 2016; 22: 806-812. 39. Lee SY. Therapeutic Drug Monitoring of Biologic Agents in the Era of Precision Medicine. Ann Lab Med. 2020; 40: 95-96. 40. Perry M, Abdullah A, Frleta M, MacDonald J, McGucken A. The potential value of blood monitoring of biologic drugs used in the treatment of rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2020; 12: 1759720X20904850. 41. Jenkins PV, Bowyer A, Burgess C, Gray E, Kitchen S, Murphy P, Platton S, Riddell A, Chowdary P, Lester W. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Center Doctors’ Organisation guideline. Haemophilia. 2020; 26: 151-155. 42. Lehtinen AE, Lassila R. Do we need all that emicizumab? Haemophilia. 2022; 28: e53-e55. 43. Coppola A, Castaman G, Santoro RC, Mancuso ME, Franchini M, Marino R, Rivolta GF, Santoro C, Zanon E, Sciacovelli L, Manca S, Lubrano R, Golato M, Tripodi A, Rocino A, ad hoc Working G. Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia. 2020; 26: 937-945. 1
RkJQdWJsaXNoZXIy MTk4NDMw